Cell Line

Claudins are a family of proteins, which play a role in maintaining tight cell junctions. Differentclaudin subtypes are expressed on different tissues.Claudin18 isoform 2 (CLDN18.2) expressionin normal tissues is restricted to cells of the gastric mucosa and is absent from other healthytissues However, CLDN 18.2 is expressed in 70% of primary gastric adenocarcinomas and itsmetastases (101). It has also beenshown to be expressed in a number of other cancers,including pancreatic (50%), esophagus (30%) and NSCLC (25%)The restricted expressionmakes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, asevidenced by effortsto target CLDN18.2 via naked antibody and CAR-T modalities.

Please note this product may be subject to fees, we invite you to contact your local office. The untransduced T cells are produced by mock lentiviral transduction of human primary CD4+CD8+ T cells. These cells are subjected to comparable manipulations as CAR-T cells: activation, spinoculation (without lentivirus), and expansion. These T cells are meant to be negative controls in experiments using lentivirus-transduced primary CAR-T cells.

Please note this product may be subject to fees, we invite you to contact your local office. The untransduced T cells are produced by mock lentiviral transduction of human primary CD4+CD8+ T cells. These cells are subjected to comparable manipulations as CAR-T cells: activation, spinoculation (without lentivirus), and expansion. These T cells are meant to be negative controls in experiments using lentivirus-transduced primary CAR-T cells.

Please note this product may be subject to fees, we invite you to contact your local office. The anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector, BPS Bioscience, #78601). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Please note this product may be subject to fees, we invite you to contact your local office. The anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Please note this product may be subject to fees, we invite you to contact your local office. Recombinant clonal CHO-K1 stable cell line constitutively expressing full-length human NCAM1 protein (Neural cell adhesion molecule 1, also known as CD56, single-pass type I membrane protein, isoform 1- Seq ID: NM_000615).  The NCAM1 (CD56) CHO cell line is provided as three different stable, clonal cell lines. Each cell line was selected for different levels of NCAM1 expression: low (L), medium (M) or high (H). Variable expression levels are advantageous for validating antibodies or compounds in binding assays.  A drug discovery program may find value in owning all three clones with differential expression of NCAM1. The surface expression of NCAM1 in each cell line was validated in parallel by flow cytometry. 

Please note this product may be subject to fees, we invite you to contact your local office. Recombinant clonal CHO-K1 stable cell line constitutively expressing full-length human NCAM1 protein (Neural cell adhesion molecule 1, also known as CD56, single-pass type I membrane protein, isoform 1- Seq ID: NM_000615).  The NCAM1 (CD56) CHO cell line is provided as three different stable, clonal cell lines. Each cell line was selected for different levels of NCAM1 expression: low (L), medium (M) or high (H). Variable expression levels are advantageous for validating antibodies or compounds in binding assays.  A drug discovery program may find value in owning all three clones with differential expression of NCAM1. The surface expression of NCAM1 in each cell line was validated in parallel by flow cytometry. 

Please note this product may be subject to fees, we invite you to contact your local office. Recombinant clonal CHO-K1 stable cell line constitutively expressing full-length human NCAM1 protein (Neural cell adhesion molecule 1, also known as CD56, single-pass type I membrane protein, isoform 1- Seq ID: NM_000615).  The NCAM1 (CD56) CHO cell line is provided as three different stable, clonal cell lines. Each cell line was selected for different levels of NCAM1 expression: low (L), medium (M) or high (H). Variable expression levels are advantageous for validating antibodies or compounds in binding assays.  A drug discovery program may find value in owning all three clones with differential expression of NCAM1. The surface expression of NCAM1 in each cell line was validated in parallel by flow cytometry. 

Please note this product may be subject to fees, we invite you to contact your local office. Recombinant clonal CHO cell line stably expressing full-length human claudin 18.1 (claudin 18 isoform 1, CLDN18, gene accession number NM_016369.4). The stable clonal cell line was selected for high levels of claudin 18.1 expression compared to the parental CHO-K1 cell line.